A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

A randomised clinical trial of an mRNA vaccine against norovirus will be launched in the UK within the next two weeks, it has ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

“Common symptoms of norovirus include nausea, diarrhoea, and vomiting,” says Sharma. “In some cases, individuals may also ...

There’s change at the top of Ogilvy Health. Kim Johnson is leaving to pursue new opportunities after three years as CEO, ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...